Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breakthrough Therapy Designation

- PMLiVE

Former Amgen R&D head Perlmutter to lead research at Merck & Co

Returns to US pharma firm after more than a decade away

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

AZ loses Crestor patent battle in Australia

Follows challenge from Apotex

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

- PMLiVE

Late-stage failure for Merck’s cilengitide in brain cancer

Integrin inhibitor unable to improve overall survival in phase III trials

- PMLiVE

Merck to develop biosimilars with Samsung-Biogen joint venture

Agreement with Samsung Bioepis covers several candidates

- PMLiVE

AZ in atherosclerosis education drive during US Heart Month

Encouraging the public to learn more about the causes of heart disease

- PMLiVE

US appeals court upholds AstraZeneca’s Seroquel XR patent

Says patent on unique formulation of antidepressant is valid

- PMLiVE

Merck settles Vytorin lawsuit for $688m

Had faced claims it held back negative data from clinical trials

- PMLiVE

Merck & Co extends autoimmune collaboration with Lycera

New deal could be worth more than $300m to the US biopharma company

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links